Andrew Kayserian is currently making significant strides as an Associate Scientist at AstraZeneca, where he is at the forefront of integrating automation and data management into the drug discovery process. With a passion for perfecting laboratory workflows, Andrew leverages his expertise in robotics and liquid...
Andrew Kayserian is currently making significant strides as an Associate Scientist at AstraZeneca, where he is at the forefront of integrating automation and data management into the drug discovery process. With a passion for perfecting laboratory workflows, Andrew leverages his expertise in robotics and liquid handling to enhance the efficiency and accuracy of experimental procedures. His current focus is on developing a robust data ecosystem that transforms lab-generated results into valuable inputs for machine learning and artificial intelligence applications. This innovative approach aims to revolutionize in-silico antibody design and protein structure prediction, ultimately contributing to the development of next-generation therapeutics.
In his role, Andrew is deeply involved in key projects that bridge the gap between traditional laboratory research and cutting-edge computational techniques. His work encompasses a variety of disciplines, including genomics, biochemistry, and oncology, allowing him to apply a multidisciplinary perspective to complex scientific challenges. By harnessing the power of Big Data and deep learning, he is committed to advancing the field of therapeutic design, ensuring that AstraZeneca remains at the forefront of biopharmaceutical innovation.
Andrew's technical skills, including proficiency in C# and platforms like Geneious, enable him to script and automate processes that streamline data collection and analysis. His dedication to enhancing laboratory efficiency through automation not only improves productivity but also paves the way for more informed decision-making in therapeutic development. As he continues to explore the intersection of automation and artificial intelligence, Andrew is poised to make a lasting impact on the future of drug discovery and personalized medicine.
